Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 2,506 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Normal Subjects Clear all
Terminated Not applicable Interventional Results available

A Comparative Evaluation of a MPS Dressing and a CMC Dressing on Subjects With Lower Extremity Venous Ulcers

NCT03903692
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Marine polysaccharide dressing, Carboxymethylcellulose dressing
Device
Lead sponsor
Medline Industries
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Fresno, California • Selma, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function

NCT03920865
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream

NCT03899064
View directory record Official record
Conditions
Photoallergy
Interventions
Induction: Application of MC2-01 Cream, irradiation, Induction: Application of MC2-01 Cream, no irradiation, Induction: Applications of MC2-01 vehicle, irradiation, Induction: Applications of MC2-01 vehicle, no irradiation, Challenge: Application of MC2-01 Cream, irradiation, Challenge: Application of MC2-01 Cream, no irradiation, Challenge: Applications of MC2-01 vehicle, irradiation, Challenge: Applications of MC2-01 vehicle, no irradiation, Challenge: Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Efficacy and Tolerance of 2 Acne Treatment Regimens on Subjects With Mild to Moderate Acne

NCT03124381
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Cleanser, Acne Mask, Cleanser, Gel-Cream, Acne Mask
Device
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years to 40 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Albuquerque, New Mexico • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 2 Interventional Results available

Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults

NCT02101736
View directory record Official record
Conditions
NF1, Neurofibromatosis, Plexiform Neurofibromas
Interventions
Cabozantinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
3 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 1 Interventional Results available

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

NCT03775434
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Experimental: B244
Drug
Lead sponsor
AOBiome LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Bryant, Arkansas • Los Angeles, California • Plainfield, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 30, 2026, 7:08 AM EDT
Recruiting Phase 2 Interventional

Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU

NCT07565506
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs)
Interventions
Antimicrobial agent
Drug
Lead sponsor
Lakewood-Amedex Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Doral, Florida • Margate, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

NCT01888874
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GLPG0634, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
28
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

NCT01820260
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol mebutate gel, placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Carmel, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 30, 2026, 7:08 AM EDT
Terminated Phase 1 Interventional

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

NCT02365662
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma, Glioblastoma Multiforme
Interventions
ABBV-221
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks

NCT05597462
View directory record Official record
Conditions
Rosacea
Interventions
Minocycline hydrochloride capsules, Placebo
Drug · Other
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Las Cruces, New Mexico • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 1 Interventional

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

NCT00006368
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 1Phase 2 Interventional

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

NCT01082068
View directory record Official record
Conditions
Breast Cancer
Interventions
XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Fort Meyers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 1 Interventional Results available

Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects

NCT02724423
View directory record Official record
Conditions
Acute Repetitive Seizures
Interventions
NRL-1
Drug
Lead sponsor
Neurelis, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Early Phase 1 Interventional

Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People

NCT02669225
View directory record Official record
Conditions
Normal Physiology
Interventions
[18F]florbetaben
Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 2 Interventional

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

NCT05717920
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ADX-629 (Open-label)
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 3 Interventional Results available

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

NCT00122382
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, placebo, methotrexate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Huntington Beach, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 1 Interventional

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

NCT00562380
View directory record Official record
Conditions
Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ganitumab, laboratory biomarker analysis, pharmacological study, biopsy
Biological · Other · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

NCT02576860
View directory record Official record
Conditions
Rosacea
Interventions
CLS001 (Omiganan), Vehicle
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
20
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Manhattan Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 3 Interventional

Long-Term Follow-Up to the DEVO Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

NCT01891760
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Dermagraft, Profore
Device
Lead sponsor
Shire Regenerative Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Phoenix, Arizona • Fresno, California • Mather, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 2 Interventional

A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum

NCT03077750
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
VBP-245 Topical Gel, Vehicle
Drug
Lead sponsor
Veloce BioPharma LLC
Industry
Eligibility
2 Years to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Fort Washington, Pennsylvania • Greenville, South Carolina • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

NCT03823391
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ABBV-3373, Placebo for ABBV-3373, Adalimumab, Placebo for adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

NCT03875482
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Placebo solution for risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04501679
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Fountain Valley, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 30, 2026, 7:08 AM EDT